Table 1 Pathological features, treatment methods and prognosis of the included cases
First author | Case (number) | Tumor site | Gene fusion type | Initial treatment | Mitotic count(0/10 HPFs) | Atypia | Lymphatic metastasis | IHC markers | State | Overall survival time(month) |
|---|---|---|---|---|---|---|---|---|---|---|
Chiang et al. [6] (2018) | 1 | cervix | RBPMS-NTRK3 | total abdominal hysterectomy with bilateral salpingo-oophorectomy + chemotherapy | 15 | moderate | NO | Pan-TRK, S100, SMA, H3K27me3(+), ER, PR, desmin, SOX10, CD34(-) | metastatic (vagina) | 7 |
2 | cervix | LMNA-NTRK1 | total abdominal hysterectomy with bilateral salpingo-oophorectomy +chemotherapy | 12 | moderate | NO | Pan-TRK, S100, SMA, H3K27me3(+), ER, PR, desmin, SOX10, CD34(-) | metastatic (lung, pancreatic and brain) | 78 | |
3 | cervix | TPM3-NTRK1 | total abdominal hysterectomy with bilateral salpingo-oophorectomy | 30 | severe | NO | Pan-TRK, S100, SMA, H3K27me3(+), ER, PR, desmin, SOX10, CD34(-) | survive | 2+ | |
Wells et al. [8] (2019) | 4 | cervix | TPM3-NTRK1 | radical abdominal hysterectomy, bilateral salpingectomy | 2 | severe | NO | CD34, S100, p16, Ki67, CD10(+), SOX10(-) | survive | 4+ |
Croce et al. [7] (2019) | 5 | cervix | TPM3-NTRK1 | NA | 3 | mild | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | NA | NA |
6 | cervix | TPM3-NTRK1 | NA | 3 | moderate | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | survive | 2+ | |
7 | cervix | TPM3-NTRK1 | NA | 5 | moderate | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | survive | 33+ | |
8 | cervix | TPM3-NTRK1 | NA | 50 | mild | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | survive | 12+ | |
9 | cervix | TPM3-NTRK1 | NA | 50 | mild | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | metastatic | 30 | |
10 | cervix | TPM3-NTRK1 | NA | 1 | mild | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | survive | 108+ | |
11 | cervix | EML4-NTRK3 | NA | 3 | moderate | NO | TRK, S100, CD34 (+); ER, PR, desmin (-) | metastatic | 52 | |
Gatalica et al. [11] (2019) | 12 | cervix | TPM3-NTRK1 | NA | NA | NA | NA | pan-TRK(+) | NA | NA |
Rabban et al. [9] (2020) | 13 | cervix | TPM3-NTRK1 | polypectomy | 0 | mild to moderate | No | Pan-TRK, S100, H3K27me3, Rb, p53(+), desmin, SMA, SOX10, caldesmon(-) | survive | 6+ |
14 | cervix | TPR-NTRK1 | hysterectomy, bilateral salpingectomy, and pelvic lymph node dissection | 5–18 | mild to moderate | No | Pan-TRK, S100, H3K27me3, Rb, p53(+); desmin, SMA, SOX10, Caldesmon(-) | survive | 19+ | |
15 | cervix | SPECC1L-NTRK3 | hysterectomy, bilateral salpingectomy, pelvic lymph node dissection + chemotherapy + pelvic radiotherapy+ larotrectinib | 16–20 | mild to moderate | LVSI | Pan-TRK, S100, H3K27me3, Rb, p53(+), desmin, SMA, SOX10, Caldesmon(-) | metastatic | 16 | |
Boyle et al. [10] (2020) | 16 | cervix | TPM3-NTRK1 | hysterectomy + adjuvant pelvic radiotherapy + brachytherapy | 8 | NA | NA | Pan-TRK, CD10, vimentin, CyclinD1, CD34(+), Cytokeratins, desmin, SMA, caldesmon, ALK1, S100, SOX10(-) | survive | 11+ |
Wong et al. [12] (2020) | 17 | cervix | NTRK3 | hysterectomy and bilateral salpingo-oophorectomy | 15 | mild | NO | Pan-TRK, S100, CD34, SMA(+), keratins, ER, PR, SOX10, desmin, Cyclin D1(-) | NA | NA |
Hodgson et al. [13] (2021) | 18 | cervix | SPECC1L-NTRK3 | hysterectomy, bilateral salpingo-oophorectomy and omentectomy | 0 | mild to moderate | NA | S100, CD34, SMA, ER, PR, H3K27me3(+), pan-cytokeratin, epithelial membrane antigen, desmin, myogenin, SOX10, Melan-A, ALK1, neuro-Filament (-) | survive | 8+ |
Munkhdelger et al. [14] (2021) | 19 | cervix | DLG2-NTRK2 | tumor excision +larotrectinib +chemotherapy | NA | severe | NA | Collagen IV, P16(+); CK7, CK19, EMA, S-100, SMA, ER, PR, CD56 (-) | survive | 23+ |
Dang X et al. [15] (2022) | 20 | cervix | EML4-NTRK3 | hysterectomy and bilateral salpingo-oophorectomy + pelvic lymph node dissection +chemotherapy | >10 | severe | NO | S100, CD34, Pan-TRK, vimentin(+); SOX10, desmin, ALK, Caldesmon, MyoD1, Myogenin (-) | metastatic (brain, lung and vagina) | 12 |
Xiaoqi Li [16] (2023) | 21 | Cervix | EML4-NTRK3 | hysterectomy and bilateral salpingo-oophorectomy + pelvic lymph node dissection +chemotherapy | NA | NA | No | S-100, H3K27ME3, pan-TRK (+), SOX10, ER, PR, CD10, SMA, Desmin, Caldesmon, Ki-67(-) | survive | 20+ |
22 | Cervix | NTRK3— | hysterectomy and bilateral salpingo-oophorectomy + pelvic lymph node dissection | NA | NA | No | S-100, CD34, NTRK1, pan-TRK, H3K27ME3(+), SOX10(-) | survive | 11+ | |
Current Case | 23 | Cervix | TFG-NTRK3 | total abdominal hysterectomy with bilateral salpingo-oophorectomy | NA | NA | No | CD34, pan-TRK(roche), H3K27ME3, S-100(+), HMB45, STAT6, Desmin, SMA(-) | survive | 31+ |